National Organization for Rare Disorders, Inc.
It is possible that the main title of the report Chandler's Syndrome is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.
Related Disorders List
Information on the following diseases can be found in the Related Disorders section of this report:
Chandler's syndrome (CS) is a rare eye disorder in which the endothelium, the single layer of cells lining the interior of the cornea, proliferates causing distortion of the iris, corneal edema, and unusually high pressure in the eye (glaucoma). CS is one of three syndromes affecting the eyes (progressive iris atrophy and Cogan-Reese syndrome are the other two) that make up the iridocorneal endothelial syndrome. Chandler's syndrome affects females more often than males and usually presents in young adulthood to middle age.
Most often the condition affects one eye only but the fellow eye often has subclinical involvement. The combination of high pressure within the eye (glaucoma) and corneal edema can result in reduced vision with pain.
Chandler's syndrome is characterized by proliferation of the cells lining the cornea, swelling of the cornea with distortion of the iris and glaucoma (optic nerve damage from high pressure) within the eye.
The pupil of the eye appears to be out of place, i.e. located in an out-of-the-ordinary position and distorted in shape and size (corectopia). In Chandler's syndrome, whatever iris atrophy occurs is mild when compared to that associated with progressive iris atrophy and Cogan-Reese syndrome. Typically, the corneal endothelium presents as a hammered, silver surface on the back of the cornea.
The disorder may cause blurred vision, pain in the eye with eventual loss of vision. Usually only one eye is affected; however, the other eye may, very rarely, be clinically involved.
The single layer of cells lining the inside of the surface of the cornea is known as the endothelium. One of the roles played by the endothelium is to pump aqueous humor (fluid inside the eye) from the cornea. If the behavior of the endothelium is interrupted (as in Chandler's syndrome), the pumping action fails, and fluid accumulates in the cornea (corneal edema) resulting in blurred vision.
The exact cause of Chandler's syndrome is not known. Some researchers suspect that inflammation or chronic viral infection may be the cause of the disease.
Chandler's syndrome is a very rare disorder that affects females more often than it does males. The disorder usually appears during young adult to middle aged years.
Symptoms of the following disorders can be similar to those of Chandler's syndrome. Comparisons may be useful for a differential diagnosis:
Progressive (or essential) iris atrophy is a very similar disorder to Chandler's syndrome and their symptoms may even overlap. Progressive iris atrophy is characterized by gross distortion of the pupil eye and the development of holes in the iris. This condition also causes increased intraocular pressure and corneal edema. If left untreated, vision loss may occur.
Cogan-Reese syndrome is characterized by distortion of iris tissue and the development of small wart-like growths on the iris. Increased pressure within the eye and corneal swelling are also evident. This disorder differs from Cogan corneal dystrophy, which is inherited as an autosomal dominant disorder. (For more information on this disorder, choose "Cogan-Reese" as your search term in the Rare Disease Database.)
Glaucoma occurs as a secondary characteristic of Chandler's syndrome. If left untreated, the increased pressure may affect the optic nerve, resulting in eventual blindness. Some symptoms for persons to be aware of are: blurred vision, rainbow colored halos around lights, and loss of side vision resulting in "tunnel vision". A simple test can measure the pressure in a person's eye, and this testing is recommended annually for persons over age 40, along with a complete eye exam. Treatment may consist of medicated eye drops and if these are unsuccessful surgery may be necessary.
Iridocorneal epithelial syndrome (ICE) is an umbrella term used to include the essential or progressive iris atrophy, Cogan-Reese syndrome, and Chandler's syndrome. The three disorders share symptoms such as corneal endothelial dysfunction and iris atrophy.
Treatment of Chandler's Syndrome usually involves the use of drops in the eyes to control the glaucoma and swelling (edema). Prostaglandin analogs, beta blockers, alpha-2 agonists and carbonic anhydrase inhibitors are drugs used for this purpose. If these methods are unsuccessful surgery may be indicated. Keratoplasty for corneal edema, and trabeculectomy for glaucoma are surgical methods used to treat Chandler's Syndrome. Laser surgery is rarely effective.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
For information about clinical trials conducted in Europe, contact:
Shields MB. Iridocorneal Endothelial Syndromes. In: NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:649.
Kanski JJ. Ed. Clinical Ophthalmology. 4th ed. Butterworth-Heinemann. Oxford, UK; 1999:233-34.
Geyer O, Neufelder M, Michaeli-Cohen A, et al. Radiation-induced Chandler's syndrome. Isr Med Assoc J. 2000;2:241-42.
Huna R, Barak A, Melamed S. Bilateral iridocorneal endothelial syndrome presented as Cogan-Reese and Chandler's syndrome. J Glaucoma. 1996;5:60-62.
Hirst LW, Bancroft J, Yamauchi K, et al. Immunohistochemical pathology of the corneal endothelium in iridocorneal endothelial syndrome. Invest Ophthalmol Vis Sci. 1995;36:820-27.
Hemady RK, Patel A, Blum S, et al. Bilateral iridocorneal endothelial syndrome: case report and review of the literature. Cornea. 1994;13:368-72.
Devine N. ed. ICE Syndrome Chat Highlights. "ICE Syndrome" July 23, 2003.
Facts About The Cornea and Corneal Disease. National Eye Institute (NEI). 2010 Available at: http://www.nei.nih.gov/health/cornealdisease/#g Accessed:February 6, 2013.
111 E 59th St
New York, NY 10022-1202
Schepens Eye Research Institute
20 Staniford Street
Boston, MA 02114-2500
National Association for Parents of Children with Visual Impairments (NAPVI)
P.O. Box 317
Watertown, MA 02272-0317
Prevent Blindness America
211 West Wacker Drive
Chicago, IL 60606
NIH/National Eye Institute
31 Center Dr
Bethesda, MD 20892-2510
Genetic and Rare Diseases (GARD) Information Center
PO Box 8126
Gaithersburg, MD 20898-8126
For a Complete Report
This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.
The information provided in this report is not intended for diagnostic purposes. It is provided for informational purposes only. NORD recommends that affected individuals seek the advice or counsel of their own personal physicians.
It is possible that the title of this topic is not the name you selected. Please check the Synonyms listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report
This disease entry is based upon medical information available through the date at the end of the topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease Database completely current and accurate. Please check with the agencies listed in the Resources section for the most current information about this disorder.
For additional information and assistance about rare disorders, please contact the National Organization for Rare Disorders at P.O. Box 1968, Danbury, CT 06813-1968; phone (203) 744-0100; web site www.rarediseases.org or email email@example.com
Last Updated: 2/7/2013
Copyright 1993, 1997, 2004, 2010, 2013 National Organization for Rare Disorders, Inc.
Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.